BRPI0815493A2 - COMPOUND, USE OF A COMPOUND, PHARMACEUTICAL COMPOSITION, PAIN THERAPY METHOD, AND PROCESS FOR PREPARING A COMPOUND. - Google Patents

COMPOUND, USE OF A COMPOUND, PHARMACEUTICAL COMPOSITION, PAIN THERAPY METHOD, AND PROCESS FOR PREPARING A COMPOUND.

Info

Publication number
BRPI0815493A2
BRPI0815493A2 BRPI0815493-7A2A BRPI0815493A BRPI0815493A2 BR PI0815493 A2 BRPI0815493 A2 BR PI0815493A2 BR PI0815493 A BRPI0815493 A BR PI0815493A BR PI0815493 A2 BRPI0815493 A2 BR PI0815493A2
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutical composition
therapy method
pain therapy
Prior art date
Application number
BRPI0815493-7A2A
Other languages
Portuguese (pt)
Inventor
Sara Beha
William Brown
Shawnn Johnstone
Ziping Liu
Daniel Page
Miroslaw Tomaszewski
Zhong-Yong Wei
Shi Yi Yue
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0815493A2 publication Critical patent/BRPI0815493A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
BRPI0815493-7A2A 2007-08-17 2008-08-15 COMPOUND, USE OF A COMPOUND, PHARMACEUTICAL COMPOSITION, PAIN THERAPY METHOD, AND PROCESS FOR PREPARING A COMPOUND. BRPI0815493A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95647807P 2007-08-17 2007-08-17
PCT/GB2008/050713 WO2009024819A1 (en) 2007-08-17 2008-08-15 Cannabinoid receptor ligands

Publications (1)

Publication Number Publication Date
BRPI0815493A2 true BRPI0815493A2 (en) 2015-02-10

Family

ID=39930420

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815493-7A2A BRPI0815493A2 (en) 2007-08-17 2008-08-15 COMPOUND, USE OF A COMPOUND, PHARMACEUTICAL COMPOSITION, PAIN THERAPY METHOD, AND PROCESS FOR PREPARING A COMPOUND.

Country Status (16)

Country Link
US (2) US20090062251A1 (en)
EP (1) EP2190838A1 (en)
JP (1) JP2010536737A (en)
KR (1) KR20100061491A (en)
CN (1) CN101827838A (en)
AR (1) AR067954A1 (en)
AU (1) AU2008290325A1 (en)
BR (1) BRPI0815493A2 (en)
CA (1) CA2696697A1 (en)
CL (1) CL2008002431A1 (en)
MX (1) MX2010001574A (en)
PE (1) PE20090598A1 (en)
RU (1) RU2010102992A (en)
TW (1) TW200908963A (en)
UY (1) UY31294A1 (en)
WO (1) WO2009024819A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062251A1 (en) * 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
WO2010147791A1 (en) * 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
EP2509937B1 (en) * 2009-12-11 2014-10-08 Bayer Intellectual Property GmbH Method for producing 2,2-difluorethylamine and its salts starting from difluoroacetonitrile
JP5841361B2 (en) * 2011-06-29 2016-01-13 壽製薬株式会社 Tricyclic compound and pharmaceutical composition containing the same
JP6106452B2 (en) * 2012-12-05 2017-03-29 公益財団法人微生物化学研究会 Compound, method for producing the same, and method for producing oseltamivir phosphate
BR112015031432A2 (en) 2013-06-25 2017-07-25 Bristol Myers Squibb Co carbazole carboxamide compounds useful as kinase inhibitors
UY35625A (en) 2013-06-25 2014-12-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware TETRAHYDROCARBAZOL AND CARBAZOL CARBOXAMIDA COMPOUNDS REPLACED AS QUINASA INHIBITORS
GB201312768D0 (en) * 2013-07-17 2013-08-28 Ge Healthcare Ltd Work-up procedure
US10023534B2 (en) 2014-10-24 2018-07-17 Bristol-Myers Squibb Company Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK
MA40301B1 (en) 2014-10-24 2019-12-31 Bristol Myers Squibb Co Indolecarboxamide compounds useful as kinase inhibitors
US10266491B2 (en) 2014-10-24 2019-04-23 Bristol-Myers Squibb Company Carbazole derivatives
EP4110463A1 (en) * 2020-02-24 2023-01-04 Galyan Bio, Inc. Indole compounds for the treatment of neurodegenerative diseases
WO2023025915A1 (en) * 2021-08-25 2023-03-02 Galyan Bio, Inc. Protein-oligomer binding agents and therapeutic uses thereof
EP4140481A1 (en) * 2021-08-26 2023-03-01 Galyan Bio, Inc. Protein-oligomer binding agents and therapeutic uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
WO2003087037A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
US20100113502A1 (en) * 2005-03-22 2010-05-06 Astrazeneca Ab Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands
US20090062251A1 (en) * 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002

Also Published As

Publication number Publication date
TW200908963A (en) 2009-03-01
CN101827838A (en) 2010-09-08
AU2008290325A1 (en) 2009-02-26
CA2696697A1 (en) 2009-02-26
JP2010536737A (en) 2010-12-02
PE20090598A1 (en) 2009-06-10
KR20100061491A (en) 2010-06-07
EP2190838A1 (en) 2010-06-02
AR067954A1 (en) 2009-10-28
MX2010001574A (en) 2010-03-15
CL2008002431A1 (en) 2009-06-05
WO2009024819A1 (en) 2009-02-26
US20090062251A1 (en) 2009-03-05
UY31294A1 (en) 2009-03-31
US20110160180A1 (en) 2011-06-30
RU2010102992A (en) 2011-09-27

Similar Documents

Publication Publication Date Title
BRPI0815493A2 (en) COMPOUND, USE OF A COMPOUND, PHARMACEUTICAL COMPOSITION, PAIN THERAPY METHOD, AND PROCESS FOR PREPARING A COMPOUND.
BRPI0914927A2 (en) compound, pharmaceutical composition, methods for inhibiting fak function and cancer treatment, use of a compound, and process for preparing a compound
BRPI0812851A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS FOR TREATMENT OF A DISEASE AND CONDITION IN AN INDIVIDUAL, PROCESS FOR PREPARING A COMPOUND, AND USE OF A COMPOUND
BRPI1006162A2 (en) "compound, process for preparing a compound, pharmaceutical formulation, and use of a compound".
BRPI0813237A2 (en) COMPOUND, METHOD FOR PREPARING COMPOUND, COMPOSITION, MEDICINE, AND, USE OF COMPOUND.
BRPI0922475A2 (en) compound, pharmaceutical composition, method for treating cancer, and use of a compound.
BRPI0910734A2 (en) compound, pharmaceutical composition, and process for preparing a compound or a pharmaceutically acceptable salt thereof.
BRPI0818244A2 (en) Compound, pharmaceutical composition, use of a compound, and method for treating a disorder or disease
BRPI0810354A2 (en) COMPOUND, USE OF A COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHOD OF TREATING A PAIN DEVICE
BRPI0818533A2 (en) compound, pharmaceutical composition, and process for the preparation of a compound
BRPI0816881A2 (en) Compound, pharmaceutical composition, use of a compound, and methods for treating diseases or disorders and for preparing a compound.
BRPI0912348A2 (en) 3-aminocarbazole compound, pharmaceutical composition, method for preparing a 3-aminocarbazole compound, use of a 3-aminocarbazole compound, and method for treating or preventing disease
BRPI0811275A2 (en) COMPOUND, PROCESS FOR PREPARING THEREOF, PHARMACEUTICAL COMPOSITION, USE OF COMPOUND, AND METHOD FOR TREATING DISEASE
BR122020011920A2 (en) compound, pharmaceutical composition, method of treating a disease, use of a compound, and processes for preparing a compound, and for manufacturing a compound
BRPI0821299A2 (en) Compound, process for preparing same, pharmaceutical composition, process for preparing same, use of a compound, and method for treating or reducing the risk of a disease or condition.
BRPI0917458A2 (en) compound, method of treating disease and conditions, pharmaceutical composition, method for treating or preventing disease, and use of a compound
BRPI0913585A2 (en) compound, method for making a compound, pharmaceutical composition, use of a compound, and method for treating or preventing disorders
BRPI0907977A2 (en) Compound, pharmaceutical composition, use of a compound, and method for treating or preventing disease
BRPI0816331A2 (en) Compound, use of a compound, pharmaceutical composition, and process for preparing a compound.
BRPI0612254A2 (en) compound, pharmaceutical formulation, combination, and process for preparing a compound
BRPI0907974A2 (en) Compound, pharmaceutical composition, use of a compound, and method for treating or preventing disease
BRPI1013396A2 (en) compound, combination pharmaceutical, use of a compound, method for treating a disease or condition, and process for the preparation of a compound.
BRPI0822946A2 (en) Carboxyamide derivative, process for preparing carboxyamide derivative, pharmaceutical composition and use of carboxyamide derivative
BRPI0817721A2 (en) Compound, pharmaceutical composition, method of treatment, and process for preparing a compound
BRPI0914371A2 (en) "compound, pharmaceutical composition, use of a compound, method of treating an individual, and combination product"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.